1、0-30 dayshost宿主宿主cure rate治愈率治愈率Normal正常正常TCRb b KOT细胞受体敲除细胞受体敲除Nude裸鼠裸鼠IFN-g g KO咖玛干扰素敲除咖玛干扰素敲除IL-4 KO白介素白介素-4敲除敲除10/100/30/200/2010/10tumor/straincure ratetumor size(day)MCA203/B6MCA105/B6MCA205/B6Sa1/AB6F1CT-26/CB6F1MCA101/B6B16/B6Lewis lung/B6Pan02/B6immunogenicyesyesyesyesyesnonononono13-17 mm(
2、14)10-14 mm(14)9-15 mm(14)12-22 mm(10-14)10-13 mm(14)7-15 mm(10-14)4-13 mm(7-14)4T1/CB6F15-14 mm(7-14)6-10 mm(14)5-17 mm(7-12)5/54/54/512/156/100/100/100/100/100/5donor cells输入输入细胞细胞treatment治疗治疗cure rate治愈率治愈率nonenave T cellstumor-immune T cellsIL-12salinesalineIL-12IL-12Cy+IL-120/10assembly of pre
3、-existing immunity in T cell-deficient host0/80/81/109/1210/10tumor-immune T cellsnave T cellstumor-immune T cellsnave T cellsCy+IL-120/5cure ratetreatmentCy+DCResponsesregr.relapse2/10progressionregression0/1010/10Medium sized(8-11 mm)MCA207 tumor used.Cy=120mg/kg given on day 21DC=cultured immatur
4、e DC at 1x106 given intratumor two days after Cy Dox dose and routecure ratei.v.at 16mg/kgi.t.at 10mg/kgi.t.at 5mg/kgi.t.at 2.5mg/kg80%100%20%0%cure rate（治愈率）（治愈率）Treatment治疗手段治疗手段None无无Dox alone单独阿霉素单独阿霉素IL-12 alone单独白介素单独白介素12Dox+IL-12阿霉素加白介素阿霉素加白介素1280%0%0%0%cure rate（治愈率）（治愈率）Treatment治疗手段治疗手段No
5、ne无无Gem alone at 2.5-10mg/kgIL-12 alone单独白介素单独白介素12Gem-50mg/kg+IL-1280%0%0%0%Gem-20mg/kg+IL-12Gem-10mg/kg+IL-1220%40%cure rate治愈率治愈率treatment治疗治疗Gem aloneIL-12 alone0/50/5Gem+IL-12Gem+DC0/50/5Gem+DC+IL-124/5DC alone0/5cure rateTumor modelMCA2070/10Pan02vinblastin+IL-120/100/50/20drug/treatmentMCA207MCA207paclitaxal+IL-125-FU+IL-12Cy+IL-12cure rateTumor modelMCA20710/10Cy+IL-121/101/100/10drug/treatmentMCA207MCA207Cy+IL-2Cy+IFN-gCy+IL-23Cy+TNFaMCA207MCA2070/10Uno K,Mitsuishi Y,Tanigawa M,et al.Cancer Immunol Immunother 52:33-40,2003
